Skip to main content

A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients with Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, and High Risk Myelodysplastic Syndrome

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Mustang Bio

Start Date

September 27, 2019

End Date

October 31, 2024
 

Administered By

Duke Cancer Institute

Awarded By

Mustang Bio

Start Date

September 27, 2019

End Date

October 31, 2024